When.com Web Search

  1. Ads

    related to: pravastatin 10 mg teva 771

Search results

  1. Results From The WOW.Com Content Network
  2. Pravastatin - Wikipedia

    en.wikipedia.org/wiki/Pravastatin

    The 3α-hydroxyisomeric metabolite of pravastatin is also an active HMG-CoA reductase inhibitor with approximately 2.5-10% the potency of the parent compound. Pravastatin has a plasma half-life of 1.8 hours whereas this active metabolite has a half-life up to 77 hours.

  3. Fenofibrate/pravastatin - Wikipedia

    en.wikipedia.org/wiki/Fenofibrate/pravastatin

    Pravastatin belongs to the group called statins. [2] It reduces total blood cholesterol by blocking the action of 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA) reductase, an enzyme in the liver involved in the production of cholesterol. [ 2 ]

  4. Teva to pay $225 million fine and divest cholesterol drug to ...

    www.aol.com/finance/teva-pay-225-million-fine...

    Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholesterol to settle price-fixing charges from the US Department of Justice, the agency ...

  5. Teva Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Teva_Pharmaceuticals

    Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs , but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing ...

  6. The generic drug maker Teva Pharmaceuticals agreed Monday to pay $225 million to settle price-fixing charges related to sales of a major cholesterol-lowering drug. The U.S. Department of Justice ...

  7. PROVE-IT TIMI 22 - Wikipedia

    en.wikipedia.org/wiki/PROVE-IT_TIMI_22

    The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 trial, also known as PROVE-IT TIMI 22, was a randomized, double-blind, clinical trial that recruited 4,162 people admitted within 10 days of an acute coronary event and randomised them to the lipid-lowering drugs pravastatin (40 mg) or atorvastatin (80 mg) and a 10-day course of the ...